353 Targeted Axillary Dissection Does Benefit Patients with a Single Positive Node Prior to Neoadjuvant Chemotherapy

Abstract Aim Targeted Axillary Dissection (TAD) is a procedure where positive axillary nodes are clipped with view to sentinel lymph node dissection plus removal of post-neoadjuvant therapies (NACT) rather than clearance (ANC), reducing morbidity. This study aimed assess whether patients single undergoing NACT would benefit from TAD. Method Patients planned for TAD post-NACT were identified the surgical diary March 2020 – July 2022. Data recorded age, histopathology, MRI response and procedure. Results Eighteen women identified, mean age 46.7 (33- 63 years). 44% (8) had ER positive, HER2 negative invasive ductal carcinoma (IDC), 28% (5) IDC, 22% (4) triple IDC 6% (1) lobular carcinoma. Treatment on was complete in (4), near or very good 11%(2), partial 61% (11) patient having stable disease. Four including who no chemotherapy opted ANC post-NACT. Only 17% (1/6) whereas 58% (7/12) Conclusions Although numbers our small, did have NACT. Larger multicentre studies needed confirm this determine response.